Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease

MP. Bonaca, DL. Bhatt, RF. Storey, PG. Steg, M. Cohen, J. Kuder, E. Goodrich, JC. Nicolau, A. Parkhomenko, J. López-Sendón, M. Dellborg, A. Dalby, J. Špinar, P. Aylward, R. Corbalán, MT. Abola, EC. Jensen, P. Held, E. Braunwald, MS. Sabatine,

. 2016 ; 67 (23) : 2719-28. [pub] 20160401

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024088

BACKGROUND: Peripheral artery disease (PAD) is associated with heightened ischemic and bleeding risk in patients with prior myocardial infarction (MI). OBJECTIVES: This study evaluated the efficacy and safety of ticagrelor on major cardiovascular (CV) events and major adverse limb events in patients with PAD and a prior MI. METHODS: PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin. History of PAD was obtained at baseline. Occurrences of major adverse cardiovascular events (MACE) (defined as CV death, MI, or stroke) and major adverse limb events (MALE) (defined as acute limb ischemia or peripheral revascularization for ischemia) were recorded in follow-up. RESULTS: A total of 1,143 patients (5%) had known PAD. In the placebo arm, those with PAD (n = 404) had higher rates of MACE at 3 years than those without (n = 6,663; 19.3% vs. 8.4%; p < 0.001), which persisted after adjusting for baseline differences (adjusted hazard ratio: 1.60; 95% confidence interval: 1.20 to 2.13; p = 0.0013), and higher rates of acute limb ischemia (1.0% vs. 0.1%) and peripheral revascularization procedures (9.15% vs. 0.46%). Whereas the relative risk reduction in MACE with ticagrelor was consistent, regardless of PAD, patients with PAD had a greater absolute risk reduction of 4.1% (number needed to treat: 25) due to their higher absolute risk. The absolute excess of TIMI major bleeding was 0.12% (number needed to harm: 834). The 60-mg dose had particularly favorable outcomes for CV and all-cause mortality. Ticagrelor (pooled doses) reduced the risk of MALE (hazard ratio: 0.65; 95% confidence interval: 0.44 to 0.95; p = 0.026). CONCLUSIONS: Among stable patients with prior MI, those with concomitant PAD have heightened ischemic risk. In these patients, ticagrelor reduced MACE, with a large absolute risk reduction, and MALE. (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS-TIMI 54]; NCT01225562).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024088
003      
CZ-PrNML
005      
20170908094922.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacc.2016.03.524 $2 doi
035    __
$a (PubMed)27046162
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bonaca, Marc P $u TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts. Electronic address: mbonaca@partners.org.
245    10
$a Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease / $c MP. Bonaca, DL. Bhatt, RF. Storey, PG. Steg, M. Cohen, J. Kuder, E. Goodrich, JC. Nicolau, A. Parkhomenko, J. López-Sendón, M. Dellborg, A. Dalby, J. Špinar, P. Aylward, R. Corbalán, MT. Abola, EC. Jensen, P. Held, E. Braunwald, MS. Sabatine,
520    9_
$a BACKGROUND: Peripheral artery disease (PAD) is associated with heightened ischemic and bleeding risk in patients with prior myocardial infarction (MI). OBJECTIVES: This study evaluated the efficacy and safety of ticagrelor on major cardiovascular (CV) events and major adverse limb events in patients with PAD and a prior MI. METHODS: PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin. History of PAD was obtained at baseline. Occurrences of major adverse cardiovascular events (MACE) (defined as CV death, MI, or stroke) and major adverse limb events (MALE) (defined as acute limb ischemia or peripheral revascularization for ischemia) were recorded in follow-up. RESULTS: A total of 1,143 patients (5%) had known PAD. In the placebo arm, those with PAD (n = 404) had higher rates of MACE at 3 years than those without (n = 6,663; 19.3% vs. 8.4%; p < 0.001), which persisted after adjusting for baseline differences (adjusted hazard ratio: 1.60; 95% confidence interval: 1.20 to 2.13; p = 0.0013), and higher rates of acute limb ischemia (1.0% vs. 0.1%) and peripheral revascularization procedures (9.15% vs. 0.46%). Whereas the relative risk reduction in MACE with ticagrelor was consistent, regardless of PAD, patients with PAD had a greater absolute risk reduction of 4.1% (number needed to treat: 25) due to their higher absolute risk. The absolute excess of TIMI major bleeding was 0.12% (number needed to harm: 834). The 60-mg dose had particularly favorable outcomes for CV and all-cause mortality. Ticagrelor (pooled doses) reduced the risk of MALE (hazard ratio: 0.65; 95% confidence interval: 0.44 to 0.95; p = 0.026). CONCLUSIONS: Among stable patients with prior MI, those with concomitant PAD have heightened ischemic risk. In these patients, ticagrelor reduced MACE, with a large absolute risk reduction, and MALE. (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS-TIMI 54]; NCT01225562).
650    _2
$a adenosin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D000241
650    _2
$a senioři $7 D000368
650    _2
$a Aspirin $x aplikace a dávkování $7 D001241
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $x epidemiologie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a ischemie $x epidemiologie $x prevence a kontrola $x chirurgie $7 D007511
650    _2
$a dolní končetina $x krevní zásobení $x chirurgie $7 D035002
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu $x epidemiologie $x prevence a kontrola $7 D009203
650    _2
$a onemocnění periferních arterií $x epidemiologie $7 D058729
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $7 D010975
650    _2
$a antagonisté purinergních receptorů P2Y $x aplikace a dávkování $x škodlivé účinky $7 D058921
650    _2
$a sekundární prevence $7 D055502
650    _2
$a cévní mozková příhoda $x epidemiologie $x prevence a kontrola $7 D020521
650    _2
$a transplantace cév $x statistika a číselné údaje $7 D058017
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Bhatt, Deepak L $u TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts.
700    1_
$a Storey, Robert F $u Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
700    1_
$a Steg, Ph Gabriel $u French Alliance for Cardiovascular Trials, Université Paris-Diderot, Paris, France.
700    1_
$a Cohen, Marc $u Cardiovascular Division, Newark Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.
700    1_
$a Kuder, Julia $u TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts.
700    1_
$a Goodrich, Erica $u TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts.
700    1_
$a Nicolau, José C $u Heart Institute (InCor)-University of São Paulo Medical School, São Paulo, Brazil.
700    1_
$a Parkhomenko, Alexander $u Ukranian Strazhesko Institute of Cardiology, Kiev, Ukraine.
700    1_
$a López-Sendón, José $u Hospital Universitario La Paz, Instituto de Investigación La Paz, Madrid, Spain.
700    1_
$a Dellborg, Mikael $u Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
700    1_
$a Dalby, Anthony $u Life Fourways Hospital, Randburg, South Africa.
700    1_
$a Špinar, Jindřich $u University Hospital, Jihlavska, Brno, Czech Republic.
700    1_
$a Aylward, Philip $u Division of Medicine, Cardiac & Critical Care Services, Flinders Medical Centre, South Australia, Australia. $7 gn_A_00010588
700    1_
$a Corbalán, Ramón $u Cardiovascular Division, Pontificia Universidad Católica de Chile, Santiago, Chile.
700    1_
$a Abola, Maria Teresa B $u Philippine Heart Center, University of the Philippines College of Medicine, Manila, Philippines. $7 gn_A_00000650
700    1_
$a Jensen, Eva C $u AstraZeneca R&D, Mölndal, Sweden.
700    1_
$a Held, Peter $u AstraZeneca R&D, Mölndal, Sweden.
700    1_
$a Braunwald, Eugene $u TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts.
700    1_
$a Sabatine, Marc S $u TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts.
773    0_
$w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 67, č. 23 (2016), s. 2719-28
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27046162 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170908095523 $b ABA008
999    __
$a ok $b bmc $g 1239769 $s 985001
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 67 $c 23 $d 2719-28 $e 20160401 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace